

Supplementary Material

Supplemental materials to:

Cost-effectiveness analysis of COVID-19 mRNA XBB.1.5 Fall 2023 vaccination in the Netherlands

Methods

Calculation of unvaccinated hospitalization risk

The hospitalization risk for the unvaccinated population was calculated based on data before the initial COVID-19 vaccine rollout during the pandemic, corrected for the delta and omicron variants of the virus. In the table below, this can be calculated as: $a \times b \times c$.

Age group	Risk COVID hospitalization ¹ <i>a</i>	Relative risk pre-delta vs. delta variant (95% CI) ² <i>b</i>	Relative risk omicron vs. delta variant ³ <i>c</i>	Calculated risk hospitalization unvaccinated
20-29 years	0.14%	1.93 (1.84 – 2.03)	0.43 (0.37 – 0.49)	0.12%
30-39 years	0.59%		0.31 (0.28 – 0.35)	0.35%
40-49 years	1.00%		0.20 (0.17 – 0.23)	0.39%
50-59 years	2.50%		0.14 (0.12 – 0.17)	0.68%
60-69 years	7.20%		0.14 (0.12 – 0.16)	1.95%
70-79 years	10.0%		0.20 (0.17 – 0.24)	3.86%
80+ years	32.0%		0.33 (0.28 – 0.39)	20.38%

Calculation of risk of infection

The risk of infection was calculated using the hospitalization risk for the unvaccinated (see above), the number of hospitalization in the period September 2022 to July 2023⁴, the vaccination coverage in both the general population and the hospitalized population⁵, and statistics on the size of the general population⁶.

The results are displayed on the following page.

	Hospitalizations	Vaccination coverage	Unvaccinated hospitalizations ²	Calculated risk of hospitalization ¹	Backcalculated number of cases ²	Unvaccinated population ²	Risk of COVID-19 infection ^{1,2}
January							
20-29 years	25	10%	22	0.12%	19,366	2,233,707	0.87% (0.60% - 1.25%)
30-39 years	49	10%	44	0.35%	12,493	2,171,853	0.58% (0.39% - 0.82%)
40-49 years	60	17%	50	0.39%	12,902	2,157,398	0.60% (0.43% - 0.82%)
50-59 years	161	17%	134	0.68%	19,782	2,440,051	0.81% (0.60% - 1.09%)
60-64 years	130	42%	75	1.95%	3,876	639,365	0.61% (0.43% - 0.83%)
65-69 years	219	42%	127	1.95%	6,529	564,123	1.16% (0.83% - 1.59%)
70-79 years	670	42%	389	3.86%	10,067	523,291	1.92% (1.30% - 2.91%)
80+ years	898	53%	422	20.38%	2,071	275,081	0.75% (0.35% - 1.77%)
February							
20-29 years	40	1%	40	0.12%	34,083	2,233,707	1.53% (1.06% - 2.19%)
30-39 years	62	1%	61	0.35%	17,388	2,171,853	0.80% (0.54% - 1.15%)
40-49 years	91	25%	68	0.39%	17,681	2,157,398	0.82% (0.60% - 1.14%)
50-59 years	173	25%	130	0.68%	19,208	2,440,051	0.79% (0.59% - 1.07%)
60-64 years	167	48%	87	1.95%	4,464	639,365	0.70% (0.50% - 0.96%)
65-69 years	244	48%	127	1.95%	6,522	564,123	1.16% (0.83% - 1.59%)
70-79 years	814	48%	423	3.86%	10,966	523,291	2.10% (1.42% - 3.17%)
80+ years	1084	57%	466	20.38%	2,287	275,081	0.83% (0.38% - 1.95%)
March							
20-29 years	36	13%	31	0.12%	26,957	2,233,707	1.21% (0.84% - 1.73%)
30-39 years	67	13%	58	0.35%	16,513	2,171,853	0.76% (0.50% - 1.07%)
40-49 years	86	27%	63	0.39%	16,264	2,157,398	0.75% (0.54% - 1.02%)
50-59 years	208	27%	152	0.68%	22,478	2,440,051	0.92% (0.68% - 1.23%)
60-64 years	216	47%	114	1.95%	5,885	639,365	0.92% (0.66% - 1.27%)
65-69 years	295	47%	156	1.95%	8,037	564,123	1.42% (1.03% - 1.97%)
70-79 years	1015	47%	538	3.86%	13,937	523,291	2.66% (1.81% - 4.04%)
80+ years	1330	58%	559	20.38%	2,741	275,081	1.00% (0.46% - 2.34%)
April							
20-29 years	15	15%	13	0.12%	10,974	2,233,707	0.49% (0.34% - 0.71%)
30-39 years	23	15%	20	0.35%	5,538	2,171,853	0.26% (0.17% - 0.36%)
40-49 years	31	24%	24	0.39%	6,104	2,157,398	0.28% (0.20% - 0.39%)
50-59 years	72	24%	55	0.68%	8,101	2,440,051	0.33% (0.24% - 0.45%)
60-64 years	71	51%	35	1.95%	1,788	639,365	0.28% (0.20% - 0.38%)
65-69 years	138	51%	68	1.95%	3,476	564,123	0.62% (0.44% - 0.84%)

	Hospitalizations	Vaccination coverage	Unvaccinated hospitalizations ²	Calculated risk of hospitalization ¹	Backcalculated number of cases ²	Unvaccinated population ²	Risk of COVID-19 infection ^{1,2}
70-79 years	435	51%	213	3.86%	5,522	523,291	1.06% (0.72% - 1.60%)
80+ years	611	62%	232	20.38%	1,139	275,081	0.41% (0.19% - 0.97%)
May							
20-29 years	6	14%	5	0.12%	4,441	2,233,707	0.20% (0.14% - 0.29%)
30-39 years	15	14%	13	0.35%	3,654	2,171,853	0.17% (0.11% - 0.24%)
40-49 years	14	23%	11	0.39%	2,793	2,157,398	0.13% (0.09% - 0.18%)
50-59 years	39	23%	30	0.68%	4,446	2,440,051	0.18% (0.13% - 0.24%)
60-64 years	56	51%	27	1.95%	1,410	639,365	0.22% (0.16% - 0.30%)
65-69 years	57	51%	28	1.95%	1,436	564,123	0.25% (0.18% - 0.35%)
70-79 years	220	51%	108	3.86%	2,793	523,291	0.53% (0.36% - 0.81%)
80+ years	265	59%	109	20.38%	533	275,081	0.19% (0.09% - 0.46%)
June							
20-29 years	2	0%	2	0.12%	1,721	2,233,707	0.08% (0.05% - 0.10%)
30-39 years	6	0%	6	0.35%	1,700	2,171,853	0.08% (0.05% - 0.10%)
40-49 years	4	32%	3	0.39%	705	2,157,398	0.03% (0.03% - 0.05%)
50-59 years	17	32%	12	0.68%	1,711	2,440,051	0.07% (0.06% - 0.11%)
60-64 years	15	58%	6	1.95%	324	639,365	0.05% (0.04% - 0.08%)
65-69 years	26	58%	11	1.95%	561	564,123	0.10% (0.08% - 0.16%)
70-79 years	52	58%	22	3.86%	566	523,291	0.11% (0.08% - 0.18%)
80+ years	74	65%	26	20.38%	127	275,081	0.05% (0.02% - 0.13%)
July							
20-29 years	3	25%	2	0.12%	1,937	2,233,707	0.09% (0.05% - 0.10%)
30-39 years	6	25%	4	0.35%	1,275	2,171,853	0.06% (0.02% - 0.05%)
40-49 years	4	33%	3	0.39%	694	2,157,398	0.03% (0.00% - 0.00%)
50-59 years	18	33%	12	0.68%	1,785	2,440,051	0.07% (0.03% - 0.05%)
60-64 years	12	57%	5	1.95%	265	639,365	0.04% (0.02% - 0.03%)
65-69 years	21	57%	9	1.95%	464	564,123	0.08% (0.04% - 0.07%)
70-79 years	78	57%	34	3.86%	869	523,291	0.17% (0.07% - 0.15%)
80+ years	90	80%	18	20.38%	88	275,081	0.03% (0.02% - 0.09%)
August							
20-29 years	8	21%	6	0.12%	5,440	2,233,707	0.24% (NA - NA)
30-39 years	8	21%	6	0.35%	1,790	2,171,853	0.08% (NA - NA)
40-49 years	12	34%	8	0.39%	2,052	2,157,398	0.10% (NA - NA)
50-59 years	23	34%	15	0.68%	2,247	2,440,051	0.09% (NA - NA)

	Hospitalizations	Vaccination coverage	Unvaccinated hospitalizations ²	Calculated risk of hospitalization ¹	Backcalculated number of cases ²	Unvaccinated population ²	Risk of COVID-19 infection ^{1,2}
60-64 years	16	50%	8	1.95%	411	639,365	0.06% (NA - NA)
65-69 years	23	50%	12	1.95%	591	564,123	0.10% (NA - NA)
70-79 years	98	50%	49	3.86%	1,269	523,291	0.24% (NA - NA)
80+ years	131	66%	45	20.38%	219	275,081	0.08% (NA - NA)
October							
20-29 years	64	1%	63	0.12%	54,533	2,233,707	2.44% (1.70% - 3.51%)
30-39 years	102	1%	101	0.35%	28,606	2,171,853	1.32% (0.88% - 1.88%)
40-49 years	112	1%	111	0.39%	28,725	2,157,398	1.33% (0.96% - 1.82%)
50-59 years	293	1%	290	0.68%	42,942	2,440,051	1.76% (1.30% - 2.37%)
60-64 years	251	8%	231	1.95%	11,870	639,365	1.86% (1.35% - 2.59%)
65-69 years	402	8%	370	1.95%	19,011	564,123	3.37% (2.44% - 4.69%)
70-79 years	1242	8%	1,143	3.86%	29,602	523,291	5.66% (3.88% - 8.67%)
80+ years	1504	14%	1,293	20.38%	6,346	275,081	2.31% (1.08% - 5.50%)
November							
20-29 years	28	3%	27	0.12%	23,376	2,233,707	1.05% (0.73% - 1.50%)
30-39 years	52	3%	50	0.35%	14,289	2,171,853	0.66% (0.44% - 0.94%)
40-49 years	60	7%	56	0.39%	14,456	2,157,398	0.67% (0.49% - 0.93%)
50-59 years	131	7%	122	0.68%	18,036	2,440,051	0.74% (0.55% - 1.01%)
60-64 years	115	32%	78	1.95%	4,020	639,365	0.63% (0.48% - 0.92%)
65-69 years	185	32%	126	1.95%	6,466	564,123	1.15% (0.86% - 1.66%)
70-79 years	525	32%	357	3.86%	9,249	523,291	1.77% (1.27% - 2.84%)
80+ years	610	37%	384	20.38%	1,886	275,081	0.69% (0.32% - 1.64%)
December							
20-29 years	42	8%	39	0.12%	33,257	2,233,707	1.49% (1.03% - 2.14%)
30-39 years	82	8%	75	0.35%	21,371	2,171,853	0.98% (0.65% - 1.39%)
40-49 years	92	14%	79	0.39%	20,497	2,157,398	0.95% (0.68% - 1.30%)
50-59 years	220	14%	189	0.68%	28,009	2,440,051	1.15% (0.85% - 1.55%)
60-64 years	208	42%	121	1.95%	6,201	639,365	0.97% (0.73% - 1.40%)
65-69 years	263	42%	153	1.95%	7,841	564,123	1.39% (1.05% - 2.01%)
70-79 years	828	42%	480	3.86%	12,441	523,291	2.38% (1.70% - 3.79%)
80+ years	1083	47%	574	20.38%	2,816	275,081	1.02% (0.48% - 2.46%)

¹The vaccinated population is excluded from this analysis

²Between brackets are the low and high values used in the scenarios, based on a bootstrapped credible interval (2.5th and 97.5th percentile)

Calculation risk of Myocarditis after infection

A recent comprehensive study by the European Medicines Agency (EMA) estimated age-stratified incidence rates for myocarditis and pericarditis over the study period 2017-2019⁷. The background data presents the myocarditis/pericarditis incidence of the unvaccinated in the Netherlands:

Age-group (years)	Incidence myocarditis/pericarditis	
	Female	Male
20-29	0.006%	0.036%
30-39	0.041%	0.055%
40-49	0.024%	0.045%
50-59	0.021%	0.041%
60-69	0.028%	0.046%
70-79	0.012%	0.037%
80+	0.050%	0.046%

These data was used with the HR of 5.16 from a meta-analysis to assess the risk of myocarditis in post- COVID-19 individuals⁸. The risk difference, or the excess risk of infection-induced myocarditis, was estimated as follows:

Age-group (years)	Incidence risk of myocarditis/pericarditis		Excess risk of infection-induced myocarditis	
	Female	Male	Female	Male
20-29	0.031%	0.185%	0.025%	0.149%
30-39	0.211%	0.285%	0.170%	0.229%
40-49	0.126%	0.233%	0.102%	0.188%
50-59	0.106%	0.210%	0.086%	0.169%
60-69	0.144%	0.239%	0.116%	0.192%
70-79	0.060%	0.192%	0.049%	0.155%
80+	0.257%	0.238%	0.207%	0.192%

For scenario analysis, data from Boehmer et al. was used, a cohort study from the Centers for Diseases Control and Prevention (CDC) on patients with at least one hospital-based encounter during March 2020 to Januari 2021⁹. Data was presented per age-group. The risk of the patients with COVID-19 was compared with the risk of patients without COVID, to estimate the adjusted myocarditis risk difference, by age, of myocarditis in infected individuals. However, age-groups in the model did not align with the age-groups in Boehmer et al., therefore, an average of the two adjacent age-groups was used:

Excess risk of infection-induced myocarditis	
18-29 years	0.080%
30-39 years	0.067%
40-49 years	0.093%
50-59 years	0.137%
60-64 years	0.137%
65-69 years	0.160%
70-79 years	0.181%
80+ years	0.208%

Risk of Myocarditis after COVID-19 vaccination

The incidence rate of vaccine-induced myocarditis/pericarditis (per dose) in individuals age 18-39 years was estimated from a self-controlled case series analysis was undertaken on hospital admissions for myocarditis or pericarditis in England from February 2021 to February 2022¹⁰. The study focused on individuals eligible to receive the mRNA vaccines (BNT162b2 or mRNA-1273) for boosting. The attributable risk for an admission for myocarditis 0 to 6 days post vaccine was 2.5 (95% confidence interval [CI], 2.0-2.8) and 4.5 (95%CI, 3.9-4.8) per million vaccinations of the BNT162b2 booster and mRNA-1273 booster vaccine, respectively¹⁰.

Length of stay, costs and QALY losses of myocarditis/pericarditis

For the days of time loss of myocarditis/pericarditis after COVID-19 infection and vaccination, the length of stay from Dutch Statistics is used¹¹. These days are used to estimate both the costs and QALYs lost. Costs per hospital day were obtained from the Dutch Costing Manual (€476/day, in 2014) and a QALY loss of 0.7 was assumed (per day=0.7/365)^{12,13}:

	Days of time loss	Costs per event (€)	QALYs lost
18-29 years	4.90	2,849	0.0094
30-39 years	5.30	3,081	0.0102
40-49 years	5.30	3,082	0.0102
50-59 years	7.80	4,536	0.0150
60-64 years	10.30	5,989	0.0198
65-69 years	10.30	5,989	0.0198
70-79 years	10.40	6,048	0.0199
80+ years	10.40	6,048	0.0199


Input for calculation indirect effects

Productivity loss	
Percentage in labor force ¹⁴	%
Age group	
0-17 years	

18-29 years	83.6%
30-39 years	87.8%
40-49 years	87.1%
50-59 years	83.0%
60-64 years	64.6%
65-69 years	23.0%
70-79 years	4.4%
80+ years	0.0%

Results

CE plane



References

1. de Boer PT, van de Kasstelee J, Vos ERA, et al. Age-specific severity of severe acute respiratory syndrome coronavirus 2 in February 2020 to June 2021 in the Netherlands. *Influenza Other Respir Viruses*. 2023;17(8):e13174. doi:10.1111/irv.13174
2. Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalisation and death with the delta variant in the USA. *Lancet Infect Dis*. 2021;21(12):1629-1630. doi:10.1016/S1473-3099(21)00685-X
3. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *The Lancet*. 2022;399(10332):1303-1312. doi:10.1016/S0140-6736(22)00462-7
4. COVID-19 dataset. Accessed July 20, 2023. <https://data.rivm.nl/covid-19/>
5. RIVM. *COVID-19 ziekenhuis en intensive-care-opnames per vaccinatiestatus in Nederland (opnames 3 oktober 2022 – 29 mei 2023)*.; 2023. Accessed August 4, 2023. <https://www.rivm.nl/documenten/covid-19-ziekenhuis-en-intensive-care-opnames-per-vaccinatiestatus-in-nederland-10>

6. Centraal Bureau voor de Statistiek. Bevolking op 1 januari en gemiddeld; geslacht, leeftijd en regio. Centraal Bureau voor de Statistiek. Published May 30, 2022. Accessed April 4, 2023. <https://www.cbs.nl/nl-nl/cijfers/detail/03759ned?dl=39E0B>
7. Willame C, Dodd C, Durán C, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study. *Vaccine*. 2023;41(1):251-262. doi:10.1016/j.vaccine.2022.11.031
8. Zuin M, Rigatelli G, Bilato C, et al. One-Year Risk of Myocarditis After COVID-19 Infection: A Systematic Review and Meta-analysis. *Can J Cardiol*. 2023;39(6):839-844. doi:10.1016/j.cjca.2022.12.003
9. Boehmer TK, Kompaniyets L, Lavery AM, et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021. *Morb Mortal Wkly Rep*. 2021;70(35):1228. doi:10.15585/mmwr.mm7035e5
10. Stowe J, Miller E, Andrews N, Whitaker HJ. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England. *PLOS Med*. 2023;20(6):e1004245. doi:10.1371/journal.pmed.1004245
11. StatLine - Ziekenhuisopnamen en -patiënten; diagnose-indeling ICD-10 (3-teken niveau). Accessed November 27, 2023. <https://opendata.cbs.nl/#/CBS/nl/dataset/84069NED/table>
12. Prosser LA, Harpaz R, Rose AM, et al. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. *Ann Intern Med*. 2019;170(6):380-388. doi:10.7326/M18-2347
13. Ministerie van Volksgezondheid W en S. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg - Publicatie - Zorginstituut Nederland. Published February 29, 2016. Accessed June 20, 2023. <https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg>
14. StatLine - Werkzame beroepsbevolking; arbeidsduur, 2003-2022. Accessed November 22, 2023. <https://opendata.cbs.nl/#/CBS/nl/dataset/82647NED/table>